Benjamin Graham Detailed Fundamental Analysis

According to Validea's guru fundamental report, Regeneron Pharmaceuticals (REGN) receives a 71% rating based on Benjamin Graham's value investing strategy, which favors companies with low price-to-book and price-to-earnings ratios, low debt, and solid long-term earnings growth. While REGN passes Graham's tests for sector, sales, current ratio, long-term debt, and EPS growth, it fails the criteria for P/E and price-to-book ratios, indicating a mixed valuation profile according to this model.

Analysis

Regeneron Pharmaceuticals Inc. (REGN) has been evaluated by Validea's Benjamin Graham-based Value Investor model, receiving a score of 71%. This deep value methodology prioritizes companies with low price-to-book (P/B) and price-to-earnings (P/E) ratios, low debt, and consistent long-term earnings growth. According to the report, REGN successfully meets the criteria for its sector, sales, current ratio, long-term debt in relation to net current assets, and long-term EPS growth, indicating strong underlying business fundamentals and a healthy balance sheet. However, the company fails to meet the Graham model's specific thresholds for P/E ratio and P/B ratio. A score of 71% is below the 80% level that typically indicates 'some interest' from this particular strategy, suggesting that while REGN exhibits several favorable characteristics, its current valuation metrics do not align with the stringent criteria of a classic Graham deep value stock. This presents a mixed profile for REGN under this specific investment lens: operationally sound but not currently qualifying as undervalued by these traditional value metrics.

Key Decisions for Investors

• Investors should acknowledge Regeneron's robust operational fundamentals, evidenced by its passing grades on sales, current ratio, manageable long-term debt, and solid long-term EPS growth as per the Graham model.
• Despite these strengths, the failure to meet the P/E and P/B ratio criteria indicates that, according to this specific deep value screen, REGN may not be considered undervalued at its current market price.
• Investors strictly adhering to Benjamin Graham's deep value principles might find REGN's current valuation less compelling, warranting a cautious approach or further analysis to reconcile its operational strength with its valuation according to this model.